drugset / Trial / NCT00375661
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.
Timeline
- Start
- 2006-09
- Primary completion
- 2012-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ribavirin | Small molecule | — | — |
| Comparator | interferon alfa-2b | Protein / enzyme biologic | — | — |